of improved influenza vaccines, Sanofi Pasteur is focusing its efforts on five key pillars: antigen composition; adjuvants; induction of synergistic immunological effector functions; understanding of host immunity to influenza; and the adoption of next-generation vaccine-manufacturing platforms (Fig. 1)....
WhoNational & International Government & NGO Preparation & Response
Alternative Names:Humenza; Inactivated H1N1 vaccine - Sanofi; Influenza A (H1N1) 2009 monovalent vaccine, adjuvanted - Sanofi; Influenza A (H1N1) 2009 monovalent vaccine, non-adjuvanted - Sanofi; Influenza A(H1N1) monovalent vaccine - Sanofi; Pandemic influenza vaccine (H1N1) split virion; Panenza...
Lead Product(s) :Influenza Vaccine Therapeutic Area :Infections and Infectious Diseases Study Phase :Approved Sponsor :Not Applicable Deal Size :Not Applicable Deal Type :Not Applicable DEALS_DEV FLUBLOK® Label Updated with Safety Data for Pregnant Individuals ...
influenza vaccines, which induce mainly serum antibodies. We aimed to evaluate the safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication (M2SR) vaccine, alone or coadministered with a licensed inactivated influenza vaccine (Fluzone High-Dose Quadrivalent; hereafter referred to...
呼吸道合胞病毒减毒活疫苗 (Sanofi Pasteur): 一种免疫刺激剂药物,由Sanofi (Sanofi)公司最早进行研发,目前全球最高研发状态为临床3期,作用机制: 免疫刺激剂,治疗领域: 感染,在研适应症: 呼吸道合胞体病毒感染,在研机构: Sanofi Pasteur, Inc.,Sanofi Pasteur。
I start by that because as you know very well, it's our intention to move vaccine forward. Now you also know that there are some competitors that are moving forward on this. Interestingly, Moderna not to name it, has recognize that they need to provide efficacy data asked by the regulato...
Sanofi Pasteur, the vaccine division of Sanofi, has shipped the first of its nearly 70 million flu vaccine doses to healthcare providers for the upcoming flu season, the company announced Monday. This year's supply uses both egg-based and recombinant technologies, and includes increased ...
(RSV) infection in infants; vaccine candidates against RSV, herpes simplex virus,Streptococcus pneumoniaeand broadly protective influenza; pediatric combination vaccines; largescale cellculture-based virus production; adjuvants and immunomodulators; conjugate vaccine production; and vaccine delivery systems. ...
The joint venture currently sells 25 vaccines in 19 European countries, including Merck & Co.'s shingles vaccine Zostavax and Sanofi Pasteur's influenza vaccine Intanza. In a joint statement, they said the 50/50 joint venture has had commercial and public health success, but that it's "in ...